Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: Preliminary results of the MITO-2 randomized trial

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Pignata, Sandro ^a   Scambia, Giovanni ^b   Savarese, Antonella ^c   Breda, Enrico ^d   Scollo, Paolo ^e   De Vivo, Rocco ^f   Rossi, Emanuela ^a   Gebbia, Vittorio ^g   Natale, Donato ^h   Del Gaizo, Filomena ⁱ   Naglieri, Emanuele ^j   Ferro, Antonella ^k   Musso, Pietro ^l   D'Arco, Alfonso Maria ^m   Sorio, Roberto ⁿ   Pisano, Carmela ^a   Di Maio, Massimo ^a   Signoriello, Giuseppe ^o   Annunziata, Annalisa ^o   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

^e CANNIZZARO HOSPITAL   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g LA MADDALENA CANCER CENTER   (Italy)

^h S Massimo Hospital   (Italy)

ⁱ S G MOSCATI HOSPITAL   (Italy)

^j NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^k SANTA CHIARA HOSPITAL   (Italy)

^l Ospedale Oncologico M Ascoli   (Italy)

^m Umberto I Hospital   (Italy)

ⁿ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^o SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GLUCOSE; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIGASTRIC PAIN; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; ITALY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG DISEASE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT REDUCTION;

ADULT; AGED; AGRANULOCYTOSIS; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PARESTHESIA; POLYETHYLENE GLYCOLS; THROMBOCYTOPENIA;

EID: 33747780775     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-202     Document Type: Article

References (21)

1. Mc Guire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with placlitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. three-year results. J Natl Cancer Inst 2000, 92:699-708.
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannell RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-3200.
4. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC: Exploratory phase III study of cisplatin and paclitaxel versus carboplatin and paclitaxel in advanced ovarian cancer. J Clin Oncol 2000, 18:3084-92.
5. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003, 95:1320-29.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advance ovarian cancer in the platinum era: a metanalysis. J Clin Oncol 2002, 20:1248-59.
7. Ozols RF, Willson JK, Weltz MD, Grotzinger KR, Myers CE, Young RC: Inhibition of human ovarian cancer colony formation by Adriamicin and its metabolites. Cancer Res 1980, 40:4109-12.
8. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. J Clin Oncol 1991, 9:1668-1674.
9. A'Hern R, Gore ME: The impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995, 13:726-32.
10. Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993, 72:3671-75.
11. Sakakibara. T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB: Doxorubicin encapsulated in strerically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumors xenografts. Cancer Res 1996, 56:3743-6.
12. Vaage J, Donovan D, Uster P, Working P: Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 1997, 75:482-6.
13. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ: Phase II study of liposomal doxoribicin in refractory ovarian cancer. Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997, 15:987-93.
14. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T: Phase II study of liposomal doxorubicin in platinum-paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 2000, 18:3093-100.
15. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Analysis of toxicities and predictors of outcome. Cancer 2001, 91:90-100.
16. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomall doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312-22.
17. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95:1-8.
18. Ferrero JM, Weber B, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E: Caelyx and Carboplatin in patients with advanced ovarian cancer in late relapse (>6 months): late results of a GINECO phase II trial [abstract]. Proc Am Soc Clin Oncol 2004, 21: 53 (Abstr 5022)
19. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospect of evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-56.
20. National Cancer Institute-Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 April 30, 1999 [http://ctep.info.nih.gov.]
21. du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G: Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann Oncol 2006, 17:93-6.